Our business

Global Presence


Along with a strong foothold in India, Emcure Pharmaceuticals has built a strong network across other geographies such as Europe,Canada, Australia and South Africa.

Emcure has established its presence in over 70 locations globally, with strategic partnerships with multi-national companies while offering expertise in biologics, Novel Drug Delivery Systems, APIs, chiral molecules, peptides, polymer-based chemistry, and complex products.

Emcure has established a strong presence with fast growth in Europe and Canada, led by its differentiated product portfolio.

Emcure entered the EU market through the acquisition of Tillomed UK in 2014 and has since setup front-end offices in a number of countries in the EU with distribution networks across Europe.


Emcure entered the Canadian market through the acquisition of Marcan Pharmaceuticals in 2015 and have since scaled up the business strongly with sales growing 3 times in last the four years.


RoW Markets

Emcure has a widespread supply chain across 70+ countries with a key focus on LATAM, Middle East, Africa, Asia, Russia/CIS, Australia. Emcure leverages its differentiated portfolio of chirality, iron, complex injectables, next-gen ARVs with over 180 approved products and more than 1000 regulatory approvals in the RoW markets.

Emcure has a focused go-to market strategy which uses a mix of front-end presence, partnership presence and distributor model to target the different market dynamics through its diversified product portfolio.

With innovative products in the pipeline and differentiated portfolio of biologics, Emcure aims to continue to grow in the RoW market with deeper market penetration and calibrated strategy.

Know More About Our Offerings

Quick Explore

Left Nav
Right Nav